Enzymatica (ENZY.ST) Stock Analysis & AI Equity Report
Enzymatica (ENZY.ST) overview
Enzymatica (ENZY.ST) stock analysis and AI equity research. For the latest completed financial year, 2024, Enzymatica reported revenue of SEK 45.6m and operating profit of SEK -52.1m; the year-end share price was 1.58 SEK and market capitalisation was SEK 305m. Enzymatica is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Enzymatica's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
Figures updated on 2025-09-04. Data will be refreshed during report generation.
About Enzymatica
Enzymatica AB is a Swedish life science company that develops and markets medical devices for infection-related conditions in the upper airways. Its main product is ColdZyme, an oral spray for colds and cold-like symptoms, sold through pharmacy and other partners. The company’s growth depends on product development, clinical evidence, and geographic expansion through collaborations.
Generate the Enzymatica report
Enzymatica is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Enzymatica and represent the latest completed financial year (2024). See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.